Online inquiry

IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7239MR)

This product GTTS-WQ7239MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets STAB1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_015136.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 23166
UniProt ID Q9NY15
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7239MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4652MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-986036
GTTS-WQ7181MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ14727MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SGN-19A
GTTS-WQ8138MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HH1
GTTS-WQ14769MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SGN-35
GTTS-WQ14675MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SCT-400
GTTS-WQ15725MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA VIR-7831
GTTS-WQ10409MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LY2439821
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW